使用喹喔啉衍生物扰乱抗生存蛋白：一项构效关系研究。
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
机构信息
Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198, United States.
出版信息
Bioorg Med Chem. 2012 Apr 1;20(7):2227-34. doi: 10.1016/j.bmc.2012.02.022. Epub 2012 Feb 16.
Abstract
In HeLa cells the combinatorial knockdown of Bcl-xL and Mcl-1 is sufficient to induce spontaneous apoptosis. Quinoxaline derivatives were screened for the induction of Mcl-1 dependent apoptosis using a cell line without functional Bcl-xL. Quinoxaline urea analog 1 h was able to specifically induce apoptosis in an Mcl-1 dependent manner. We demonstrate that even small changes to 1h results in dramatic loss of activity. In addition, 1 h and ABT-737 synergistically inhibit cell growth and induce apoptosis. Our results also suggest that 1h could have therapeutic potential against ABT-737 refractory cancer.
摘要
在 HeLa 细胞中，Bcl-xL 和 Mcl-1 的组合敲低足以诱导自发凋亡。使用没有功能性 Bcl-xL 的细胞系筛选了喹喔啉衍生物诱导 Mcl-1 依赖性凋亡。喹喔啉脲类似物 1h 能够以 Mcl-1 依赖的方式特异性诱导凋亡。我们证明，即使 1h 发生微小变化，也会导致活性急剧丧失。此外，1h 和 ABT-737 协同抑制细胞生长并诱导凋亡。我们的结果还表明，1h 可能对 ABT-737 耐药的癌症具有治疗潜力。
相似文献
1
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
Bioorg Med Chem. 2012 Apr 1;20(7):2227-34. doi: 10.1016/j.bmc.2012.02.022. Epub 2012 Feb 16.
2
YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
Mol Cancer Ther. 2013 Mar;12(3):326-38. doi: 10.1158/1535-7163.MCT-12-0901. Epub 2013 Jan 16.
3
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Haematologica. 2015 Dec;100(12):1553-63. doi: 10.3324/haematol.2015.130351. Epub 2015 Oct 9.
4
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Cancer Res. 2013 Feb 15;73(4):1340-51. doi: 10.1158/0008-5472.CAN-12-1365. Epub 2012 Dec 12.
5
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Clin Cancer Res. 2008 Dec 15;14(24):8132-42. doi: 10.1158/1078-0432.CCR-08-1665.
6
pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737.
Cell Death Differ. 2013 May;20(5):755-64. doi: 10.1038/cdd.2013.6. Epub 2013 Feb 22.
7
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Cell Death Dis. 2012 Aug 9;3(8):e366. doi: 10.1038/cddis.2012.109.
8
Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
J Biol Chem. 2012 Mar 23;287(13):10224-10235. doi: 10.1074/jbc.M111.334532. Epub 2012 Feb 6.
9
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Cancer Res. 2007 Jan 15;67(2):782-91. doi: 10.1158/0008-5472.CAN-06-3964.
10
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.
引用本文的文献
1
A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network.
Molecules. 2025 Apr 30;30(9):2001. doi: 10.3390/molecules30092001.
2
Synthesis of Morpholine-, Piperidine-, and -Substituted Piperazine-Coupled 2-(Benzimidazol-2-yl)-3-arylquinoxalines as Novel Potent Antitumor Agents.
ACS Pharmacol Transl Sci. 2022 Sep 1;5(10):945-962. doi: 10.1021/acsptsci.2c00118. eCollection 2022 Oct 14.
3
Research and Development of Natural Product Tanshinone I: Pharmacology, Total Synthesis, and Structure Modifications.
Front Pharmacol. 2022 Jul 11;13:920411. doi: 10.3389/fphar.2022.920411. eCollection 2022.
4
PIDA-mediated intramolecular oxidative C-N bond formation for the direct synthesis of quinoxalines from enaminones.
RSC Adv. 2019 Mar 7;9(14):7718-7722. doi: 10.1039/c9ra01200a. eCollection 2019 Mar 6.
5
Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth.
Proc Natl Acad Sci U S A. 2022 May 3;119(18):e2115071119. doi: 10.1073/pnas.2115071119. Epub 2022 Apr 27.
6
Spirocyclic dimer SpiD7 activates the unfolded protein response to selectively inhibit growth and induce apoptosis of cancer cells.
J Biol Chem. 2022 May;298(5):101890. doi: 10.1016/j.jbc.2022.101890. Epub 2022 Apr 1.
7
Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.
Eur J Med Chem. 2021 Oct 15;222:113579. doi: 10.1016/j.ejmech.2021.113579. Epub 2021 May 30.
8
Small molecule binding to inhibitor of nuclear factor kappa-B kinase subunit beta in an ATP non-competitive manner.
Chem Commun (Camb). 2021 May 11;57(38):4678-4681. doi: 10.1039/d1cc01245b.
9
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
Bioorg Med Chem Lett. 2021 Jul 1;43:128061. doi: 10.1016/j.bmcl.2021.128061. Epub 2021 Apr 23.
10
Design, Synthesis, and Biological Evaluation of Novel Thiazolidinone-Containing Quinoxaline-1,4-di--oxides as Antimycobacterial and Antifungal Agents.
Front Chem. 2020 Aug 6;8:598. doi: 10.3389/fchem.2020.00598. eCollection 2020.
本文引用的文献
1
Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):245-8. doi: 10.1016/j.bmcl.2011.11.025. Epub 2011 Nov 11.
2
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.
3
Clinical practice. Treating smokers in the health care setting.
N Engl J Med. 2011 Sep 29;365(13):1222-31. doi: 10.1056/NEJMcp1101512.
4
GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
Cancer Lett. 2011 Oct 1;309(1):27-36. doi: 10.1016/j.canlet.2011.05.011. Epub 2011 Jun 12.
5
Divergent synthesis of unsymmetrical annulated biheterocyclic compound libraries: benzimidazole linked indolo-benzodiazepines/quinoxaline.
ACS Comb Sci. 2011 Jul 11;13(4):391-8. doi: 10.1021/co200022u. Epub 2011 Jun 7.
6
Synthesis and evaluation of quinoxaline derivatives as potential influenza NS1A protein inhibitors.
Bioorg Med Chem Lett. 2011 May 15;21(10):3007-11. doi: 10.1016/j.bmcl.2011.03.042. Epub 2011 Mar 17.
7
2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study.
Bioorg Med Chem Lett. 2011 Apr 1;21(7):1929-32. doi: 10.1016/j.bmcl.2011.02.055. Epub 2011 Feb 17.
8
Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.
Cell Death Differ. 2011 May;18(5):864-73. doi: 10.1038/cdd.2010.152. Epub 2010 Nov 26.
9
Izumiphenazines A-C: isolation and structure elucidation of phenazine derivatives from Streptomyces sp. IFM 11204.
J Nat Prod. 2010 Dec 27;73(12):1999-2002. doi: 10.1021/np100400t. Epub 2010 Nov 23.
10
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Cancer Biol Ther. 2011 Jan 15;11(2):263-76. doi: 10.4161/cbt.11.2.13959.
Zotero 插件